Sunshine Biopharma Inc. held its annual meeting of stockholders on December 11, 2025. At the meeting, Dr. Steve N. Slilaty, Mr. Camille Sebaaly, Dr. Rabi Kiderchah, Mr. David Natan, and Dr. Andrew Keller were elected as directors of the company. Stockholders also ratified the appointment of M&K CPAS, PLLC as the independent registered public accounting firm for 2025. In addition, an amendment to the 2023 Equity Incentive Plan to increase the number of shares of common stock authorized for issuance to 683,000 was approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-25-009103), on December 12, 2025, and is solely responsible for the information contained therein.
Comments